Table Of Content

AJH 1998;11:1502-1507 SUBJECT INDEX TO VOLUME 11 Atherosclerosis, 293, 882 early detection, 882 Atrial enlargement, 631 Absenteeism, 929 Atrial natriuretic factor, 1006 Acetylcholine, 328 Atrial natriuretic peptide, 1178, 1384 Acoustic quantification, 1032 Autonomic nervous system, 302, 523, 1093 Acromegaly, 591 Awareness, 744 a-Adducin, 502 Adenoma, adrenal cortical, 117 Adenosine A2a receptor, 1492 B Adolescent, 410, 418, see also age Adrenalectomy, 1 Backscatter, 1442 B-Adrenergic receptor blocker, 1S, 378, 614, 618, 1269, 1392 Baroreceptor sensitivity, 129, 130, 682 a,-Adrenoceptors, 790 Adrenocorticotropin, 796 Baroreflex, 828 Adriamycin nephropathy, 1124 sensitivity, 523, 649 Bax, 1108 Age, 425, 1006, 1374, see also elderly, children, and adolescent Bcl-2, 1108 Aging, 39S, 41S, 46S, 1056, 1295, 1405, see also elderly Benazeprilat, 59 Air traffic controllers, 208 Bezold-Jarisch reflex, 66 Albumin excretion, 1100 Birth weight, 946 Alcohol, 230, 1332 Black Caribbeans, 942, see also race and ethnic differences Aldosteronism, primary, 8, 828 Blacks, 251, see also race and ethnic differences Aldosterone, 1303 Blood pressure, 31, 46, 137, 174, 245, 357, 373, 385, 418, 539, 606, Aldosterone synthase gene, 856 659, 677, 852, 884, 946, 971, 1117, 1248, 1267, 1282, 1285S, Ambulatory blood pressure, 147, 309, 387, 403, 410, 454, 690, 820, 1303, 1319, 1332, 1369, 1374, 1480 914, 1141, 1153 ambulatory, see ambulatory blood pressure diurnal profile, 909 arterial, 328, 1110 monitor, 1486 casual, 497, 1138 monitoring, 155, 230, 272, 478, 497, 515, 532, 602, 606, 813, 852, circadian, 122, see also dipper 909, 1065, 1326, 1342, 1350, 1356, 1426 device, memory-equipped, 1413 24-h, 591, 1093, 1147 control, 302, 900, 905, 1024, 158S Ambulatory electrocardiogram monitoring, 640 flow, 190 Amlodipine, 478, 690 forearm, 1369 Androgens, 97 peripheral, 1134 Angiotensin, 715 high, 487, 998 Angiotensin converting enzyme, 363, 507 home, 820, 1141 inhibition, 387 self-measured, 165, 813, 1413 inhibitor, 163S, 170S, 322, 378, 618, 682, 697, 962, 1065, 1074, intraarterial, 1469 1080, 1087, 1269, 1288, 1295, 1392, 1433 measurement, 1486 inhibitor therapy, 165 monitoring, 208, see also ambulatory blood pressure Angiotensin I converting enzyme, 235 morning surge, 245, 1356 Angiotensin II, 137, 579, 971, 989, 177S nocturnal reduction rate, 403, see also dipper Ile°, 570 normal, 813 induced hypertension, 570 office, 602, 1147 receptor antagonist, 378, 445, 462 optimal, 877 nonpeptide, 454 validation, 1486 Val°, 570 variability, 515, 532, 828 Angiotensin receptors, 548 Blood vessels, 263, 554, 579, 989, 1108 Angiotensinogen, 439, 507, 1037 Body fat distribution, 418 Antidiabetic agent, 1134 Body mass index, 946 Antihypertensive drug therapy, 62S, 929, 1392 Body surface area, 1248 Antihypertensive treatment, 57S, 69S, 1015, 109S, 135S, 145S, 170S, Bogalusa Heart Study, 196 1868S, 739, 754, 873, 894, 987, 1258, 1266, 1267, 1379 Bradycardia, 66 nonpharmacologic, 52S Bradykinin, 1288 Antioxidants, 1450, 1480 Brain natriuretic peptide, 1006 Aorta, 54 Bufodienolide, 796 Arachidonic acid, 803 L-Arginine, 1267 Artery, 1108 compliance, 293 mesenteric, 54 stiffness, 856 Caffeine, 1426 subclavian, 1469 Calcium, 88, 839, 1199 Arteriolar structure dysfunction, 879 antagonist, 163S, 170S, 322, 378, 471, 618, 1269, 1392, 1420 Arteriolosclerosis, 954 dihydropyridine, 1074 Association study, 125, 1492 cytosolic, 81 AT, receptor antagonist, 59 intracellular, 113, 767 AT, receptor antagonist, 357 ion receptor, 1117 Atenolol, 272, 494, 597, 1244 mobilization, 1208 © 1998 by the American Journal of Hypertension, Ltd. 0895-7061/98/$19.00 Published by Elsevier Science, Inc. PII S0895-7061(98)00245-3 AJH-DECEMBER 1998-VOL. 11, NO. 12 SUBJECT INDEX 1503 serum ionized, 8 Diltiazem ER, 23 Canada, 747 Dipper, 122, 280, 403, 606, 1350, see also blood pressure Canadian Heart Health Initiative, 747 Disease management, 1015S, 1035S, 109S, 135S Capillary permeability, 563 Diuretic, 59, 378, 618, 1087, 1269, 1392 Captopril, 597, 844, 989, 1178 DOC-salt hypertension, 1199 Cardiac Dog, 1199 function, 1288, 1350 beagle, 844 output, 659 Dopamine release, 1475 cardiac, see also heart, coronary Doxazosin, 1178 Cardiomyopathy, dilated, 1041 Drug, see also individual drugs Cardioprotection, 1295 choice, 618 Cardiovascular combination therapy, 163S, 145S, 158S, 170S, 322 disease, 887, 1258 effects, 322 function, 1117 fixed low-dose, 1087 reactivity, 196 multiple, 1362 risk, 31, 1825S, 1392 psychotropic, 309 risk factors, 861 safety, 471 system, 39S, 41S side effects, 309, 322, 163S Carotid artery, 387 treatment efficacy, 903 distensibility, 682 withdrawal, 462 wall thickness, 430 Carvedilol, 614, 1258 Catecholamine, 1282, 1426 Celiprolol, 1258 Cell culture, 54 Earthquake, 1138 Central nervous system, 971, 1475 Eastern Europe, 756 Children, 418, 497, see also age Echocardiography, 147, 155, 316, 387, 631, 640, 1032, 1248, 1252 Chinese population, 935, see also ethnic differences Economics, clinical, 1125 Chloride, 585 Effect model, 890 Chronobiology, 606 Efficacy, 163S Cicletanine, 579, 1384 Elderly, 39S, 46S, 525, 57S, 62S, 1024, see also age, aging Circadian rhythm, 122, 373, 690, 1342 Electrocardiography, 286 Clinical outcomes, 103S Electrolyte excretion, 935 Clinical performance, 1326 Enalapril, 23, 1267, 1295, 1433 Clinical trials, 120S, 1285 Endopeptidase, neutral, 363 Clonidine, 184, 597 Endothelin, 240, 866, 983, 1028, 1426 Clusterin, 715 endothelin-1, 554, 989, 1379, 1384 Cocaine, 708, 1277 endothelin-derived contracting factor, 1450 Compliance, 478, 1585, 186S endothelin-derived relaxing factor, 1450 Congestive heart failure, 874, 1041 receptor antagonists, 1379 Constant-routine protocol, 373 Endothelium, 240, 708 Coronary disease, 293 Epidemiology, 946, 1024, 138S, 1420 Coronary reserve, 813, 879 Epidermal growth factor, 715 Cost, 120S, 1269 Epinephrine, 677 analysis, 618 Epithelial sodium channel, 942 antihypertensive medications, 487 Erythrocyte, 81, 774 control, 1269 aggregability, 784 per quality-adjusted life-year, 112S Na/Li countertransport, 935 Cost-effectiveness, 1125, 1433 Ethelin-1, 548 Creatinine, 839 Ethnic differences, 196, 251, 935, 942, see also race and specific Cyclosporine, 1369 groups Cytochrome P450, 803 Etiology, 138S Cytoskeleton, 502 Exercise, 1028 capacity, 1252 tolerance, 640 D training, 73 Dehydroepiandrosterone sulfate, 532 Dental surgery, 1374 Developing countries, 487 Diabetes mellitus, 14, 302, 667, 884, 1065, 1093, 1178 Family history, 1310, 150S non-insulin-dependent, 184, 983, 1100 Fatty acid, 340 Diabetic nephropathy, 251 Felodipine, 690 Diastolic dysfunction, 631 Fibrinogen, 784 awr er eer Diastolic function, 147, 1032, 1252 Fibrinolytic function, 1266 Diet, 88, 998 Fibrinolytic system, 378 sodium intake, 1178, see also salt, sodium Fibronectin, 784 sodium reduction, 1048, see also salt, sodium Fibrosis, 879 therapy, 31 Fluorescent dye technique, 1214 Digitalis-like factor, 1 Folate, 1100 Digoxin-like immunoactivity, 667 Formulary, 471 1,25-Dihydroxycholecalciferol, 659 Fosinopril, 494 Dilevalol, 1258 France, 903 Diltiazem, 597 Free radical, 1480 1504 SUBJECT INDEX AJH-DECEMBER 1998-VOL. 11, NO. 12 G office, isolated, 820 prevalence, 744, 747, 750, 756, 763 prevention, 861 Galanin, 1475 quality of life, 186S Gender, 998, 1252, see also men and women refractory, 1362 Gene, 439 secondary, 52S polymorphism, 174, 235 spontaneous, 1450 General practice, 905 systolic, 182S Genetic hypertension, 219, 585, 866 treatment, 618 Genetic linkage, 942 two-kidney, one-clip, 1124 analysis, 251 white coat, 41, 820 Genetics, 125, 1385, 174, 316, 502, 729, 856, 1019, 1037, 1492 Hypertensive complications, 101S Germany, 750 Hypotension, 1450 Gestational age, 946 postprandial, 1356 Gestational hypertension, 839 Hypothalamus, posterior, 723 Glomerular filtration rate, 328 Hypoxia, 1028 Glomeruli, 989 Glomus tumor, 258 Glucose, 1048 metabolism, 184 Glutathione, oxidized, 921 Glycosylated hemoglobin (HbA,,), 31 Ile’-angiotensin II, 570 In situ end-labeling, 1108 Growth factor, 548, 715 Growth hormone, 591 Initial therapy, 95S Guidelines, 95S, 109S, 131, 132, 134, 877, 890, see also JNC Inositol phosphate, 219 Insulin, 54, 563, 790 actions, 1056 pressor system, 962 H receptor, 494 renal sodium handling, 962 Hamster, 866 resistance, 397, 523, 563, 844, 887, 935, 962, 1056, 1232, 1310, Health care delivery, 103S 1332, 1405 Health disease management, 103S sensitivity, 1048, 1258 Health disorders, 929 Insulin-dependent diabetes mellitus, 1093, 1178 Health maintenance organization, 471 Intranasal administration, 971 Heart, 263, see also cardiac, coronary Irbesartan, 445, 462 disease, hypertensive, 813 Isoforms, 213 failure, 1S, 1080 Isradipine, 272 congestive, 874, 1041 rate, 373, 539, 597 J variability, 196, 523, 649, 682, 1374 Height, 1248 Hemodialysis patients, 1362 Japanese, 125, see also ethnic differences Hemodynamics, 184, 614 JNC V, 62S, see also guidelines Hemoglobin, 105 JNC VI, 131, 134, see also guidelines Homocysteine, 1019, 1100 Hormone replacement therapy, 909, 1147 Hostility, 245 K Human leukocyte antigen, 729 HVJ-liposome methods, 507 Kidney, 585, see also renal Hydrochlorothiazide, 272, 597, 914, 1267 disease, 302, 983 Hypercholesterolemia, 14 fetal, 213 Hyperhomocysteinemia, 1019 porcine, 1208 Hyperinsulinemia, 667, 790, 962, 1056, 1129 Hyperlipidemia, 113, 887 stones, 46 K-pNPPase activity, 667 Hypertension, 15, 14, 31, 39S, 66, 69S, 73, 1035, 105, 1205, 122, 128S, 132, 1385, 150S, 155, 177S, 184, 203, 235, 240, 245, 258, 263, 272, 280, 316, 340, 387, 403, 425, 430, 439, 454, 462, 471, 478, 494, 502, 507, 523, 532, 548, 597, 610, 614, 631, 667, 708, 715, 723, 729, 733, 740, 744, 747, 750, 754, 756, 763, 784, 790, 796, 828, 882, 887, 890, 894, 905, 914, LDL cholesterol, 113 921, 935, 946, 954, 989, 1006, 1019, 1024, 1041, 1080, 1087, Left atrial enlargement, 732 1164, 1178, 1188, 1222, 1232, 1244, 1269, 1277, 1310, 1388, Left ventricle 1442, 1475 filling, 147, 1032 arterial, 515, 1032 function, 349 borderline, 286 geometry, 1164, 1171 chronic, 1129 hypertrophy, 1S, 147, 280, 286, 387, 425, 515, 631, 861, 1171, complications, 882 1178, 1188, 1392, 1442 essential, 8, 23, 41, 125, 137, 397, 659, 732, 774, 866, 909, 942, regression, 640 962, 1056, 1141, 1171, 1239, 1258, 1303, 1379, 1492 complete, 631 gestational, 839 mass, 410, 430, 1248 mechanism, 137 morphology, 286 mild, 602, 1248 performance, 1188 mild-to-moderate, 445 structure, 1350 nephrosclerosis, 251 Leptin, 1303 AJH-DECEMBER 1998-VOL. 11, NO. 12 SUBJECT INDEX 1505 Leukocyte, 1037 O Lipid, 31, 887 Lipid peroxide, 1480 Ob gene product, 1303 Lipoproteins, 1332 Obesity, 418, 844, 914, 1303, 1405 Lisinopril, 914, 1244 Observer bias, 1413 Losartan, 445, 548, 989 Obstetrics, 978 Lovastatin, 1222 Obstructive sleep apnea, 1282 Lymphocytes, 1388 Octreotide, 591 Osmotic stimulation, 357 Osteopontin, 954 Ouabain, 1, 1208 Quabain-like factors, 1208 Mag-fura-II, 1388 Magnesium, membrane, 1388 Major histocompatability complex, 729 Medical education, 610 Parathyroid hormone, 839 Medullary collecting duct, inner, 1208 intact, 8 Medullipin, 803 Pathophysiology, 203 Melatonin, 219 Patient education, 610 Men, 1252, see also gender PD123319, 357 Menopause, 709 Peptidases, 585 Mental arithmetic testing, 41 Peptides, 1475 Metabolic abnormalities, 935 Pharmacoeconomics, 1015, 1125, 135S Metalloprotease inhibitor, dual, 363 Pharmacologic therapy, 69S Metoprolol, 614, 649 Pharmacokinetics, 445 Mibefradil, 1461 population, 1087 Microalbuminuria, 113, 430, 884, 983, 1277, 1319 Pheochromocytoma, 117, 258 Microcirculation, 585 Physical activity, 73 Microdialysis, 723 Placebo, 597 Mitochondria, 1295 Placebo-controlled study, 445 Molecular biology, 101S Plasma Mononuclear cells, proliferation of, 1461 half-life, 690 Mortality, 14 renin activity, 462 Muscarinic receptors, 66 viscosity, 784 Myocardial apoptosis, 1295 Plasminogen activator inhibitor, 378 Myocardial infarction, 874 Plasminogen activator inhibitor-1, 235 Myocardial scintigraphy, 813 Platelet, 113, 1239 Myocardiosclerosis, 1295 function, 677 Myocardium, 1295 platelet-derived growth factor, 1239 Myocyte, isolated, 349 Plethysmography, 190 Polymorphism, 439, 502 Polymorphonuclear leukocytes, 921 Population-based survey, 903 N Potassium, 1141 Power spectral analysis, 1093 Pravastatin, 844 Na‘, see also sodium and salt Prazosin, 597 Na*/H* exchange, 81, 774, 1214 Preeclampsia, 839 Na* /Ca** exchanger, 1214 Pregnancy, 88, 852 Na*/Li* countertransport, 774 Primary care, 740 NaK-ATPase, 667, 796 Programmed cell death, 1108 Natriuresis Prospective study, 46 exaggerated, 1342 Prostate cancer, 1420 pressure, 803 Protein kinase C, 81 Necrosis, 921 Proteinase inhibitors, 585 Neonatal salt restriction, 385 Proteinuria, 302, 1074 Nephrectomy, bilateral, 1362 Psychotropic medication, 309 Nephropathy, progression of, 1124 Nephrosclerosis, 697 Nicotine, 677, 1153 Nifedipine, 471, 1461 Nifedipine SR, 478 Nilvadipine, 122 QT dispersion, 280, 286, 1164 Nitric oxide, 66, 240, 697, 708 Quality of care, 120S Nitric oxide synthase, 125 Quality of life, 31, 57S, 1125, 186S L-Nitro-arginine methyl ester, 1232 Quinapril, 631 N®-Nitro-L-arginine methyl-ester (L-NAME), 66, 1129 Nondipper, 122, 403, 1356, see also blood pressure Norepinephrine, 1048, 1288 R release, 219 Nuclear magnetic resonance, 340 Number needed to treat (NNT), 1285, 138S Race, 1379, see also ethnic and individual groups Nutrition, 31, see also diet Radioimmunoassay, 866 1506 SUBJECT INDEX AJH-DECEMBER 1998-VOL. 11, NO. 12 Ramipril, 649 Specialist care, 740 Rat, 579, 796 Specificity, 1319 fructose-fed, 563 Spectral analysis, 129, 130, 539 heart, isolated working, 1288 Sphygmomanometer, electronic, 978 kidney, 213 Spirapril, 272 normotensive, 88 Stress, 41S, 208, 1138, 1248 Sabra, 790 Stroke, 874 spontaneously hypertensive, 59, 349, 1475 Studies of Left Ventricular Dysfunction (SOLVD), 1433 Sprague-Dawley, 563, 998 Superoxide dismutase, 1480 Wistar-Kyoto, 767, 1475 Superoxide release, 921 Reading effect, 203 Sympathetic nerve activity, 219, 723, 1310 a-Receptor antagonists, 378 Sympathetic nervous system, 708, 1048, 1282, 1374 Red blood cells, 105 Systolic Hypertension in the Elderly Program (SHEP), 57S Reliability, 1413 Renal, see also kidney artery stenosis, 46S, 1080 T disease, 46S, 1585S end-stage, 46S failure Talking effect, 203 acute, 1080 Target organ damage, 230, 732, 813, 1171 chronic, 989, 1087 Tasosartan, 454 nondiabetic, 1074 Telemetry, 59 Temocapril, 962 function, 137, 357 hypoperfusion, 1124 Thalassemia, 539 nerves, 723 Thiazolidinedione, 1134 perfusion pressure, 803, 1199 Thrombocytes, 1388 plasma flow, 97 B-Thromboglobulin, 677, 1239 effective, 659 Thrombosis, 1019 transplant, 497 Thromboxane, 240 vascular Tissue plasminogen activator, 378, 1266 impedance, 430 Tobacco, smokeless, 1153 resistance, 97 Tomography scanner, 293 Transforming growth factor-B,, 715 tone, 1222 Renin, 213, 1303, 1426 Treatment, 132, 263, 39S, 744, 747, 763, 150S, see also Renin system analysis, 894, 170S antihypertensive treatment Renin-angiotensin system, 137, 177S, 213, 316, 570 withdrawal, 165 Renin-angiotensin-aldosterone system, 856 Trough-to-peak ratio, 454 Reproducibility, 852 Tubulointerstitial disease, 954 Resistance vessels, 1214 Tumor, nonfunctioning, 117 Risk, 740 absolute, 95S cardiovascular, 31, 182S, 861, 1392 U multifactorial, 150S Risk factor reduction, 95S Ultrasonic tissue characterization, 155, 1442 Riva-Rocci, 1469 Ultrasonography, 293 United Kingdom, 754 Urinary excretion albumin, 1065, 1093 calcium, 8 Salt, see also sodium, Na* endothelin-1, 1342 resistance, 790 sodium, 1342 neonatal restriction, 385 Urine, human, 1208 sensitivity, 397, 790 US population, 744 Screening test, 1319 Seasonal effects, 602 Sensitivity, 1319 Sensory nerve, 1117 Sequence analysis, 129, 130 Sexual activity, 1244 Vagal tone, 649 Sexual dimorphism, 97 Validation, 978 Sexual dysfunction, 733 Validity, 1326 Simulated patients, 610 Val°-angiotensin II, 570 Skeletal muscle, 585 Valsartan, 59 Sleep, 245 Vanadium diascorbate, 1208 Sleep apnea, 272 Variability, 1356 cemPWorYw e repeN Small G proteins, 1222 Vascular Smoking, 14, 1093, 1153 growth, 54 Smooth muscle, 105 hypertrophy, 844 Social economic factors, 900 reactivity, 73, 88 Sodium, 357, 502, 1199, see also Na”, salt remodeling, 507, 554 channel, epithelial, 942 resistance, 1369 intake, 998 smooth muscle, 579, 1108 nitroprusside, 1384 Vasoconstriction, 1214 Spain, 763 Vasodilating B-blocker, 1258 AJH-DECEMBER 1998-VOL. 11, NO. 12 SUBJECT INDEX 1507 Vasodilation, 1450 Vasodilator hormone, 137 Vasodilator therapy, 1041 Vasopressin, 357, 579, 971, 1208 White coat effect, 203, 820 Vasorelaxation, 1384 White coat hypertension, 41, 820 Ventriculoarterial coupling, 1188 Women, 733, 1252, see also gender Verapamil, 1129 postmenopausal, 1147 Videodensitometric, 155 Work efficiency, 1188 meScreoeee p en eyee~ rn t | | AJH 1998;11:1508-1556 AUTHOR INDEX TO VOLUME 11 Aakhus, S., see Soma, J. Agueli, M.D., see Andronico, G. Alcocer, L., Mosler, A.L., Velasco, M., Aalkjer, C., see Sihm, I. Aguilar, R., see Blanco, F., Ruiz-Nodar, Meny, M.G., Reyes, A.G., LASTLHY Aanderud, S., see Gerdts, E. J.M. Group: Edema as a Symptom in a AASK Study Group, see Phillips, R.A. Aguilera, M.T., see De la Sierra, A., Sierra, Study of Lasidipine Versus Abad, E., Luque-Otero, M., Galgo, A., c. Nifedipine GITS in Essential Banuelos, F., Martell, N.: Metabolic Agulova, L.P., Konyaeva, E.B.: Many-Days Hypertension, 261A Risk Factors and Target Organ Cyclicity and Mutual Mutual Alcocer, L., Reyes, A.J., Meny, M.G., Damage in White Coat Synchronization of Hemodynamic Espinas, R.D., Velasco, M., Hypertensives, Essential and Vegetative Functions in LASTLHY Group: Pharmacotherapy Hypertensives, and Normotensives, Patients With Essential of Essential Hypertension With Two 219A Hypertension, 162A Calcium Antagonists: Blood Abate, D., see Nolly, H. Agulova, L.P., Konyaeva, E.B., Sarychev, Pressure Responses Over Sixteen Abate, N., Kizilbash, A., Sander, K., V.T.: Are There Any Predictors of Weeks Analyzed by the Montevideo Howell-Stampley, T.S., Victor, R.G.: Hypertensive Crisis?, 162A Mathematical Model (MMM), 128A Sympathetic Neural Activation in Ahmed, A., Gupta, G., Szabolcs, M., Alcocer, L., Reyes, A.J., Velasco, M., Meny, Skeletal Muscle Correlates With Danziger, R.S.: Expression Pattern M.G., Mosler, A.L., LASTLHY Abdominal Obesity in Healthy, of Soluble Guanylyl Cyclase in Dahl Group: Late Decrease in Body Young African-American Women, Salt-Sensitive and Salt Resistant Weight During Therapy of Essential 167A Rats, 24A Hypertension With Calcium Abate, N.I., see Kizilbash, A.M. Ahmed, K., see Lazarus, J.H. Antagonists, 128A Abe, F., see Omata, K., Yamada, M. Aihara, A., see Munakata, M. Alcocer, L., see Mosler, A.L., Reyes, A.J. Abe, I., see Fujishima, S., Matsumura, K. Airaksinen, K.E.J., see Pikkujamsa, S.M., Alda, O., Gimenez, I., Droy-Lefaix, M.T., Abe, K., see Munakata, M. Vesalainen, R.K. Garay, R.P.: Inhibition By (-)- Abesadze, T., see Burkadze, N. Airoldi, F., see Marana, I. Cicletanine of the Calcium Signal Abraham, A.A., see Velasquez, M.T. Akamizu, T., see Sellitti, D.F. Elicited By Vasopressin in the A10 Abraham, N.G., see da Silva, J-L. Akers, W.S., see Johnson, J.A. Vascular Smooth Muscle Cell Line, Abrahamsen, J., see Jespersen, B. Abrahamsson, T., Brandt-Eliasson, U., Akkus, N.I., Sung, B.H., Malireddi, K., 113A Morsing, P., Sjoqvist, P.O..: Gollamudi, M., Wilson, M.F.: Alderman, M.H.: Risk Factors and Risk Candesartan Causes a Long-Lasting Insulin Attenuates Angiotensin II- Profiling as a Basis for Antagonism of the Angiotensin II Induced Venoconstriction in Man, Individualizing Treatment, 246A Receptor Mediated Contractile 151A Alderman, M.H., Cohen, H., Kivlighn, S., Effects in Isolated Vascular Akkus, N.I., see Malireddi, K. Madhavan, S.: Does Treatment- Preparation: A Comparison With Akofglu, E., see Tezcan, H. Mediated Increase in Uric Acid Losartan and its Active Metabolite Akpaffiong, M.J., Taylor, A.A.: Reduce the Cardioprotective Effect (Exp 3174), 36A Antihypertensive and Vasodilator of Diuretics in Hypertensive Abrahamsson, T., see Morsing, P. Actions of Antioxidants in Patients?, 16A Abrahao, S.B., see Santello, J.L. Spontaneously Hypertensive Rats, Alderman, M.H., Cohen, H., Madhavan, S.: Abril, J.L., see Puras, A. 1450 Epidemiology of Risk in Acampora, R., see Giugliano, D. Akuzawa, N., Nakamura, T., Kurashina, Hypertensives: Experience in Accurso, V., see Michieletto, M., Winnicki, T., Saito, Y., Hoshino, J., Sakamoto, Treated Patients, 874 M. H., Sumino, H., Ono, Z., Nagai, R.: Alderman, M.H., see Fang, J., Gerber, L.M., Achimastos, A.D., see Stergiou, G.S. Antihypertensive Agents Prevent Lackland, D.T., Roman, M.J. Adeagbo, A.S.O.: Impaired Endothelium- Nephrosclerosis and Left Aldigier, J.C., see Ruilope, L.M. And Sodium Pump-Mediated Ventricular Hypertrophy Induced in Alesse, E., see Pastore, L. Hyperpolarization in Mesenteric Rats by Prolonged Inhibition of Alexander, M., Tekawa, I.S., Hunkeler, Bed of DOCA-Salt Hypertensive Nitric Oxide Synthesis, 697 E.M., Fireman, B.F., Selby, J.V., Rats, 27A Alam, H., Lopez-Candales, A.: Obesity is Massie, B.M., Cooper, W.D.: Adeagbo, A.S.O., see Kawabe, T. Under-Diagnosed in Hypertensive Evaluating Hypertension Control in Adler, E., see Kassler-Taub, K. Patients in the Primary Care Setting, a Large HMO, 225A Adrian, M.]J., see Sobrino, J. 132A Alexander, M., see Hunkeler, E.M. Afthonidis, D., see Zarifis, J. Albani, A., see Franceschini, L. Alexiadis, S., see Paletas, K. Agabiti-Rosei, E., see Muiesan, M.L. Albano, J.B.M., see Campbell, S.K. Alfie, J., see Przygoda, P. Agarwal, M., Lynn, K.L., Richards, A.M., Nicholls, M.G.: Hyponatremic- Albano, J.D.M., see Perry, K. Aliaga, L., see Mediavilla, J.D. Albarrdan, O.G., see Villa, E. Alkoutami, G.S., see Tabriz, A.N. Hypertensive Syndrome in Renal Alberti, C., see Marana, I. Allegra, A., see Buemi, M. Ischemia: An Under-recognized Albrecht, F.E., Xu, J., Moe, O.W., Hopfer, Allen, K., Golden, L.H., Ching, M.L, Disorder, 42A U., Simonds, W.F., Orlowski, J., Forrest, A., Niles, C., Niswander, P., Agata, J., see Miyazaki, Y. Agewall, S., see Fagerberg, B. Jose, P.A.: Regulation of Na* /H* Barlow, J., Izzo, J.L., Jr.: Exchanger-3 (NHE-3) By G-Protein Normalization of Hypersensitive Agraz, I., see Mora-Macia, J. Aguado Guerrero, F., see Sanchez- Subunits in Renal Brush Border Responses During Ambulatory Chaparro, M.A. Membranes, 156A Surgical Stress By Perioperative Aguas Lopes, F., see Maldonado, J. Albrecht, F.E., see Xu, J. Music, 19A Albrecht, R.F., see Danilov, S.M., Miletich, Allen, K., Gross, A., Izzo, J.L., Jr.: Influence DJ. of Aging, Social Support, and Pet Albrecht, R.F., Jr., see Miletich, D.J. Ownership on Blood Pressure in Page numbers followed by A indicate ab- Albright, G.M., see Victor, R.G., Zhang, W. Women at Home and in Physicians’ stracts. Alcazar, J.M., see Campo, C. Offices, 134A © 1998 by the American Journal of Hypertension, Ltd. 0895-7061/98/$19.00 Published by Elsevier Science, Inc. PII S0895-7061(98)00244-1 AJH-DECEMBER 1998-VOL. 11, NO. 12 AUTHOR INDEX 1509 Allen, K., Shykoff, B.E., Izzo, J. L., Jr.: Andresdottir, M.B., van Hamersvelt, H.W., Araujo, M.T.M., Barker, L.A., Cabral, A.M., Cognitive Appraisal of Threat or van Helden, M.J., van de Bosch, Vasquez, E.C.: Inhibition of Nitric Challenge Predicts Hemodynamic W.J.H.M., Valk, I.M., Huysmans, F. Oxide Synthase Causes Profound Responses to Mental Arithmetic and Th. M.: A New Method for Enhancement of the Bezold-Jarisch Speech Tasks, 134A Quantitative Assessment of Edema Reflex, 66 Allen, K., see Shykoff, B.E. During Chronic Treatment With Arco, C., see Ruiz-Nodar, J.M., Saez, T., Allen, T.J., see Cooper, M.E. Calcium Entry Blockers, 100A Suarez, C, Saez, T. ALLHAT Group, see Cushman, W.C., Andreucci, M., see Russo, D. Arez, I., see Zimlichman, R. Nwachuku, C.E. Andrews, B., see Ogonowski, A.A. Argenio, G.F., see Bernini, G.P. Almeida, L., see Amado, P. Andronico, G., Agueli, M.D., Mule, G., Argenziano, L., Fratta, L., Larrni, F., Almeida, P., see Pego, M. Ferraro-Mortellaro, R., Mangano, Trimarco, B.: Efficacy of Eprosartan in Elderly Patients With Almendros, M.C., see Armario, P., Torres, M.T., Cerasola, G.: Menopause and Hypertension, 83A G. Blood Pressure Variability, 59A Ariga, H., see Hase, M.O. Aloisi, C., see Buemi, M. Andronico, G., see Cerasola, G. Armario, P., Hernandez del Rey, R., Alonso, M., see Saez, T., Suarez, C, Saez, T. Angelsen, B.A.J., see Soma, J. Torres, G., Martin-Baranera, M., Alonso, T., see Garcia, F., Rueda, D. Angerosa, M., see Toblli, J.E. Almendros, M.C., Pardell, H.: Alonso-Galicia, M., see Jiang, J. Angius, M.F., see Tonolo, G. Relationship Between Alpert, B., see Calzolari, A. Angotti, S., see German6, G. Cardiovascular Reactivity of Heart Alsina, J., see Martinez-Castelao, A. Anis Anwar, Y., White, W.B., Mansoor, Rate and Blood Pressure to a Alterini, B., see Mori, F. G.A., Tendler, B.E.: Structured Stressful Interview and Hyperaldosteronism is a Common Altieri, P.I., see Gonzalez-Fernandez, R.A. Early Target Organ Damaged in Cause of Secondary Hypertension Alvarez, C.A., see Gonzalez, C.L. Untreated Mild Hypertension. Missed By Primary Care Physicians Alvarez, E., see Mengden, T. Hospitalet Study, 191A and Associated With Alvarez, V., see Lurbe, E. Armario, P., see Hernandez del Rey, R., Normokalemia, 199A Alvarez-Guerra, M., Nazaret, C., Garay, Pardell, H., Torres, G. R.P.: Erythrocyte Na-K-Ci Anis, Y., see Mansoor, G.A. Armengod, M.E., see Redon, J. Ansari, A., see Niarchos, A.P. Cotransporter NKCC1 Isoform in Armentano, R., see Espinosa, J.D. Dahl Salt-Sensitive Rats, 155A Antic, V., Tempini, A., Motani, J.P.: Arnett, D.K., see Rose, K.M. Control of Blood Pressure During Alvarez-Guerra, M., see Vargas, F. Arons, E., see Silverberg, D. Alves, F., see Pego, M. the Development of Obesity- Arpinelli, F., see Zaninelli, A. Induced Hypertension, 88A Arruda, J.A.L., see Brecklin, C.S., Mo, W. Alves, J.M., see Diaz, M.E. Antithrombotic Trialists’ Collaboration, see Arsenio, A., see Amado, P. Alves, M., see Maldonado, J. Neal, B. Arteaga, J., Petrina, E., Calderon, D., Alves, Z., see Maldonado, J. Antochi, F., see Dorobantu, M. Asiron, M.: Treatment With Amado, P., Vasconcelos, N., Almeida, L., Antonio, M.T., see De la Sierra, A. Enalapril to Lithiasis and Nazare, J., Carmona, J.: Refractory Antony, I., see Nitenberg, A. Hypertensive Patients Causes a Hypertension in Elderly Anversa, P., Leri, A., Kajstura, J.: Decrease in Urinary Citrate Hypertensive Patients. Importance Mechanical Forces and Myocyte Excretion, 115A of Ambulatory Blood Pressure Death, 236A Artigao, L.M., Llavador, J.J., Sanchis, C., Monitoring, 49A Anzalone, D., see Cooper, M., Porush, J.G. Lopez Abril, J., Torres, C., Rubio, Amado, P., Vasconcelos, N., Nazare, J., APNET Investigators, see Girerd, X. M., Vidal, A., Naharro, F., Puras, A., Arsenio, A., Santos, I., Almeida, L., Appel, L.J., see Vogt, T.M. Divison, J.A., Masso, J., Carrion, L.: Teles, J., Carmona, J.: Is There Any Appel, R.G., see Freedman, B.I. Evaluation of Three Devices for Association Between Ambulatory Applegate, W.B.: Quality of Life During Self-Measurement of Blood Pressure Pulse Pressure and Left Ventricular According to the British Antihypertensive Treatment: Mass in Essential Hypertensive Hypertension Society Protocol: The Lessons From the Systolic Patients?, 68A Hypertension in the Elderly OMRON M1 MxX2 Y M4, 60A Amar, J., Bieler, L., Salvador, M., Artigao, L.M., see Masso, J. Program, 57S Chamontin, B.: Duration of Artigao, M., see Martinez, E., Puras, A. Aragon, J., see Motero, J. Hypertension and Vascular Changes Artwohl, J.E., see Gulati, A. Arakawa, K., see Saku, K. in Essential Hypertensives, 193A Asaad, M.M., see Trippodo, N.C. Aranda, F.J., see Aranda, P. Amar, J., see Vernier, I. Asagami, T., see lida, S., Takahashi, A. Aranda, J., see Fernandez-Andrade, C. Ambrosioni, E., see Bacchelli, S., Borghi, C., Asaji, T., see Kitagawa, I. Aranda, P., Aranda, F.J., Lopez de Ascot Steering Committee, see Dahlof, B. Degli Esposti, D., Veronesi, M. Novales, E., Garcia-Arnes, J.A., Ashino, K., Gotoh, E., Sumita, S., Ochiai, Amenta, F., see Ferreira-de-Almeida, J.A. Contreras, J.: Amlodipine Versus H., Kimura, K., Ishii, M.: Anand-Srivastava, M.B., Palaparti, A.: Amlodipine Plus Doxazosin in Low Sympathetic Nerve Activity is Inhibition of ANP-C Receptor Doses for Treating Type 2 Diabetics Enhanced in Patients With Expression and Associated With Essential HBP and Pheochromocytoma, 200A Adenylyl Cyclase Activity By Microalbuminuria, 124A Asiron, M., see Arteaga, J. Phosphorothioate Antisense Aranda, P., Aranda, F.J., Lopez de Askari, B., McGriff, J.C., Ferreri, N.R.: Oligodeoxynucleotides, 38A Novales, E., Sola, E.: Hypocalciuric Tumor Necrosis Factor-Alpha Anand-Srivastava, M.B., see Boumati, M. and Antihypertensive Effects of Attenuates Angiotensin II-Induced Anderson, D.E., Parsons, D.J.: High Losartan Versus Responses in Vascular Smooth Resting End-Tidal CO, Association Hydrochlorothiazide in the Muscles Via an Eicosanoid- With Higher Resting Blood Pressure Hypertensive Postmenopausal Dependent Mechanism, 35A in Older Women, 217A Woman, 124A Asmar, R., see Blacher, J., Maldonado, J., Anderson, D.E., see Fedorova, O.V. Aranda, P., Martin, R., Aranda, F.J., Lopez Topouchian, J. Anderson, E.A., see Hausberg, M. de Novales, E.: Does Surgical Astorri, E., see Fiorina, P. Anderson, P.G., see Young, D.B. Menopause Increase the Salt Atienza, F., see Motero, J. Anderson, W.P., see Evans, R.G. Sensitivity in Women?, 80A ATIME Investigator Group, see Flack, J.M. Andersson, O., see Fridman, K. Aranda, P., see Fernandez-Andrade, C., Atkinson, R.W., see Cappuccio, F.P. Andreadis, E.A., see Diamantopoulos, E.J. Fernandez-Arcas, N., Munoz, E. Atlante, A., see Seccia, T.M. 1510 AUTHOR INDEX AJH-DECEMBER 1998-VOL. 11, NO. 12 Atlas, S.A., see Dolgilevich, S.M. Baigent, C., see Neal, B. Barenbrock, M:, Spieker, C., Hausberg, M., Atzeni, M.M., see Tonolo, G. Bailey, W.P., see Lackland, D.T. Kisters, K., Kosch, M., Rahn, K.H.: August, P., see Bloch, M.J. Baiocchi, M.R., see Rossi, A. Relationship Between Parathormone Aurigemma, G.P., see Wachtell, K. Bajenaru, O., see Dorobantu, M. Levels and Arterial Distensibility in Aurup, P., Smith, R.D., Goldberg, A.L, Baker, B., Helmers, K., O’Kelly, B., Tobe, Renal Transplant Recipients, 178A Snavely, D.: Long-Term Blood S.: Maritial Cohesion and Barenbrock, M., see Hausberg, M., Kisters, Pressure Control With Losartan Ambulatory Blood Pressure in Early K. Alone or in Combination With Hypertension, 78A Barg, J., see Rosen, B. Hydrochlorothiazide or Other Baker, B., O’Kelly, B., Szalai, J.P., Katic, Barker, L.A., see Araujo, M.T.M. Antihypertensive Drugs in Patients Barksdale, C.M., Burger, P.J., Cook, J.A., M., McKessock, D., Ogilvie, R., With Mild-to-Moderate Essential Nordblom, G.D., Michniewicz, B.M., Basinski, A., Tobe, S.W.: Hypertension, 110A Kirkish, L.S., Posvar, E., Strand, J.: Determinants of Left Ventricular Aurup, P., see Smith, R.D. Preliminary Pharmacokinetics of Mass in Early Hypertension, 1248 Austin, C.P.: The Genomic Revolution and CI-992 in Cynomolgus Monkey and Bakker-Arkema, R., see Black, D.M. its Implications for New Drug Human Plasma, 104A Bakris, G.: Value of Combination Therapy Discovery, 242A Barletta, G., see Lazzeri, C. for Patients With Renal Disease, Avila-Hernandez, R., see Puentes- Barlow, J., see Allen, K. 249A Arciniegas, F.F. Barna, I., Fehér, T., de Chatel, R.: Bakris, G.L.: The Role of Combination Aviles, J., see Fernandez, M. Relationship Between Blood Antihypertensive Therapy and the Avorn, J., Bohn, R., Mogun, H.: Predictors Pressure Variability and Serum Progression of Renal Disease of Medication Compliance in a Dehydroepiandrosterone Sulfate Hypertension: Looking Toward the Large Population of Hypertensive Levels, 532 Next Millennium, 1585S Patients, 232A Baron, A.D., Steinberg, H.: Elevated Free Ayoub, J.C.A., Vitola, J.V., Costa, O.M.C., Balaskas, A., see Styliadis, I. Fatty Acid (FFA) Levels Impair Delgado, A.S., Parma, A.H.C., Balbi, A.L., Franco, R.J.S., Barretti, P., Endothelium Dependent Takakura, I.T.: Losartan Improves Gavras, I., Gavras, H.: Renal Artery Vasodilation (EDV), 241A Diastolic Function of Hypertensive Clipping Attenuates the Progression Barone, C., see Gianrossi, R. Patients, 129A of Adriamycin Nephropathy, 1124 Barrett, J.D., see Kamide, K. Azam, M., see Gupta, G. Baldi, G., see Bevilacqua, M. Barrett, M., see Sherif, K. Azechi, H., see Iwata, T. Baldo, G., see Rossi, A. Barretti, P., see Balbi, A.L. Azen, S., see Lee, D.P. Baldoncini, R., see De Mattia, G., Ferri, C. Barrio, E., see Calvo, C. Azizi, M., see Chatellier, G. Baldwin, C.T., see DeStefano, A.L. Barrios, V., see Calderon, A., Campo, C. Azoubel, I., see Machado, C.E. Balitas, S.G., see Lasaridis, A.N. Barro, C., see Zaoui, P. Azqueta, M., see Sierra, C. Ballance, D.I., see Lewis, C. Barron, J.J., see Wilson, M.D. Ballarin, J., see Mora-Macia, J. Barroso, S.G., see Fagundes, V.G.A., Torres, Ballester, E., see Cases, A. M.R.S.G. B Balletta, M.M., see Russo, D. Bartel, S., Hempel, P., Karczewski, P., Balu, N., see Brand-Schieber, E. Schlegel, W.P., Krause, E.G.: Bacchelli, S., Borghi, C., Prandin, M.G., Balzan, S., D’Urso, G., Montali, U., Increased SER 16- and THR 17- Immordino, V., Ambrosioni, E.: Palmieri, S., Ghione, S.: OQuabain- Phospholamban Phosphorylation in Improved Blood Pressure Control in Like Immunoreactivity in Human Hearts of Hypertensive Rats, 92A Hypertensive and Plasma, 94A Bartolomucci, F., see Maiorano, G. Hypercholesterolemic Patients Banderas, M.J., see Fernandez-Arcas, N., Barton, M.: Endothelin, 239A Baruch, L.: The Hemodynamic and Treated with HMG-CoA Reductase Munoz, E. Hormonal Effects of AT, Receptor Inhibitors, 25A Bandinelli, S., see Dell’Omo, G., Pedrinelli, Bacchelli, S., see Degli Esposti, D., R., Penno, G. Blockade Added to ACE Inhibition Veronesi, M. Banuelos, F., see Abad, E. in Heart Failure, 252A Bach, R., see Stefanidis, I. Bao, W., see Urbina, E.M. Baruffi, M.C., see Fortini, A. Backer, A., Kramer, H.J., Kassem, R., Baptista, L., see Machado, C.E. Barzon, L., see Fallo, F. Scheersoi, A., Bokemeyer, D.: Barajas, R., see Coca, A. Bashan, N., see Raviv, Y. Characterization of Endothelin Barba, G., see Cappuccio, F.P. Basinski, A., see Baker, B. Receptors and Endothelin Synthesis Bataillard, A., see Boulanger, M. Barbagallo, M., Dominguez, L.J., in Porcine Kidney, 39A Batlle, D.C., see Lurbe, E. Putignano, E., Calcara, L., Licata, G., Backer, A., see Heidbreder, E., Kramer, H.]J., Bauduceau, B., Genés, N., Chamontin, B., Barbagallo-Sangiorgi, G.: Efficacy Vogel, V. Vaur, L., Renault, M., Etienne, S., and Tolerability of Lercanidipine Bacri, A.M., see Joannides, R., Topouchian, Marre, M.: Ambulatory Blood Versus Captopril in Patients With J. Pressure and Urinary Albumin Mild-to-Moderate Hypertension in a Badano, L., see Bertoli, D. Excretion in Diabetic (Non-Insulin- Double-Blind Controlled Study, Badia, J.M., see Cases, A. Dependent and Insulin-Dependent) 108A Baglivo, H., see Espinosa, J.D., Ramos, F. Hypertensive Patients: Relationships Barbagallo-Sangiorgi, G., see Barbagallo, Bagrov, A.Y., Droy-Lefaix, M.-T., at Baseline and After Treatment by M Dmitrieva, R.I.: Vasorelaxant Effects the Angiotensin Converting Enzyme of Cicletanine and its (+)- and (—)- Barbieri, E., see Machado, C.E. Inhibitor Trandolapril, 1065 Barbosa, A.J., see Pego, M. Enantiomers in Isolated Human Baukal, A.J., see Smith, R.D. Pulmonary Arteries, 1384 Barbry, P., see Persu, A. Baum, K.D., see Zweifler, A.J. Bagrov, A.Y., see Dorofeeva, N.A., Barcelo, P., see Mora-Macia, J. Bazzani, E., see Restori, G. Fedorova, O.V. Bardaji, A. Gutierrez, C., see Martinez-Vea, Bazzani, V., see Restori, G. Baguet, J.P., Moreau-Gaudry, A., Siche, A. Beaumont, J., see Ravassa, S. J.P., Troccaz, J., Tremel, F., Cinquin, Barenbrock, M., Spieker, C., Hausberg, M., Bechini, P., see Cuspidi, C. P., Mallion, J.M.: Reproducibility of Kisters, K., Kosch, M., Rahn, K.H.: Beck, M., see Toth, M. Measures of Parietal Thickening Relationship Between Flow- Beegom, R., Singh, R.B., Rastogi, S.S.: and of Carotid Diameter By a New Mediated Vasodilatation and Prevalence and Determinants of | Automatic Analysis Program, 185A Distensibility of the Brachial Artery Hypertension in Five Indian Cities, | Bai, H., see Saku, K. in Essential Hypertension, 71A 226A | AJH-DECEMBER 1998-VOL. 11, NO. 12 AUTHOR INDEX 1511 Beegom, R., see Singh, R.B. Bernard, D.B., Townsend, R.R., Sylvestri, Bevilacqua, M., Vago, T., Baldi, G., Beevers, D.G., Gallet, M., Middeke, M., M.F.: Health and Disease Norbiato, G.: Evidence that C-Site of Notter, T., Zilles, P.: Efficacy and Management: What Is it and Where Angiotensin Converting Enzyme is Safety of the Fixed Combination Is it Going?: What Is the Role of Responsible for Bradykinin Verapamil SR/Trandolapril 180/2 Health and Disease Management in Metabolism in Human Tissues, 13A mg in Hypertensive Patients Hypertension?, 103S Bezante, G.P., see Pontremoli, R. Insufficiently Pretreated With Bernard, D.B., see Materson, B. Bezie, Y., see Koffi, I. Trandolapril 2 mg Monotherapy, Bernardes-Silva, H., see Gerbase-DeLima, Bezrodnaya, L., Svyshchenko, E., 100A M. Kupchinskaya, E., Bobrova, E., Beevers, D.G., see Lydakis, C. Bernardini, F., see Pezza, V. Yarinkina, E.: Differences in Ionized Beevers, M., see Lydakis, C. Bernaud, C., see Mounier-Vehier, C., Calcium Distribution Between Behar, S., see Jonas, M. Blood Plasma and Cell Depending Zannad, F., Zaoui, P. Beilin, C.J.: Lifestyle and Blood Pressure: on Hypertension Grade, 155A Bernini, G., Paci, A., Sgro, M., Moretti, A., An Overview, 237A Salvetti, A.: Endogenous Digitalis- Bezrodnaya, L.V., see Bobrova, E.V. Beldekos, D., see Manolis, A.J. Bhoola, K.D., see Seedat, Y.K. Like Factor and Ouabain Bella, J.N., see Wachtell, K. Biagini, N., Lombardi, A., Pereili, P., Immunoreactivity in Bellanuova, I., see Benedetto, F.A. Roscio, G., Rocchi, A.: Effects of Adrenalectomized Patients and Bellavere, F., see Michieletto, M. Losartan on 24-Hour Blood Pressure Normal Subjects After Acute and Bellido, C.A., see Pineiro, D.J., Vazquez and its Variability in Mild-To- Prolonged Salt Loading, 1 Blanco, M. Moderate Hypertension, 262A Bellini, C., see De Mattia, G., Ferri, C., Bernini, G.P., Sgrd, M., Moretti, A., Bianchi, A., see Villatico Campbell, S. Pastore, L. Argenio, G.F., Salvetti, A.: Bianchi, G.: Alpha-Adducin and Salt Bellini, G., see Cosenzi, A., Seculin, P. Dehydroepiandrosterone-Sulphate Sensitivity, 243A Bellizzi, V., see Rao, M.A.E. and Corotid Intimal-Media Bianchi, M., see Di Bello, V. Bello, A., see Palmiero, P. Thickness in Pre and Biasin, R., see Casiglia, E. Belsha, C.W., Wells, T.G., McNiece, K.L., PostMenopausal Women, 95A Biasion, T., see Palatini, P. Seib, P.M., Plummer, J.K., Berry, Bernini, G.P., see Paci, A. Bidzinashvili, B., see Burkadze, N. P.L.: Influence of Diurnal Blood Bernobich, E., see Cosenzi, A., Seculin, P. Bieler, L., see Amar, J. Pressure Variations on Target Berruti, V., see Pontremoli, R. Bieniaszewski, L., see Szczech, R. Organ Abnormalities in Adolescents Berry, K.L., see Gatzka, C.D. Biesenbach, G., see Zazgornik, J. With Mild Essential Hypertension, Berry, P.L., see Belsha, C.W. Bigalli, G., see Maiorano, G. 410 Bertanelli, F., Fabiano, P., Guidi, A., Bihorac, A., see Tezcan, H. Beltran, B., see Mengden, T. Corsini, F., Leone, A.: Ambulatory Bilovil, A.N., see Koval, S.N. Belviso, A., see Ragonesi, P.D. Blood Pressure Monitoring in Bittencourt, M.I., see Costa, L.S. Benedetto, F.A., Tripepi, G., Mallamaci, F., Passive Smoking and Atropine Blacher, J., Djane, S., Asmar, R., London, Marino, C., Garozzo, M., Response in Healthy Volunteers, G., Safar, M.: Aortic Pulse Wave Bellanuova, I., Cataliotti, A., 263A Velocity (PWV): Marker of Seminara, G., Rapisarda, F., Bertin, P., see Girerd, X. Cardiovascular Risk in Fatuzzo, P., Bonanno, G., Bertini, A., see Di Bello, V. Hypertensive Patients, 189A Stancanelli, B., Malatino, L., Bertoli, D., Badano, L., Carratino, L., Blacher, J., Guerin, A., Pannier, B., Tassone, F., Zoccali, C.: Pulse Caudullo, M., Magliani, L., Petacchi, Marchais, S., Safar, M., London, G.: Pressure and Malnutrition are the R.: Prevalence of Echocardiographic Impact of Aortic Stiffness on Main Detriments of Vascular Damage in Dialysis Patients, 202A Patterns of Left Ventricular Survival in End-Stage Renal Failure, Geometry in Hypertensive Patients: 189A Benemio, G., see Schillaci, G. Beneshin, C.G., see Shan, J. Does it Depend on the Diagnostic Black, D.M., Bakker-Arkema, R., Benet, M.T., see Lopez-Contreras, J. Criteria Applied?, 220A Heinonen, T., Nawrocki, J.W.: Does the Presence of Either Concurrent Benetos, A., Gressin, V., Working Group Bertolini, A., see Guasti, L., Piantanida, E. | Hypertension or Non-Insulin- of the French Study: Effects of Ultra Bertolo, O., see Palatini, P. Dependent Diabetes Mellitus Affect Low-Dose Combination of Bertolotti, M., see Giusti, C. the Efficacy and Safety of Bisoprolol /Hydrochlorothiazide in Bertolozzi, I., see Vanni, S. Systolic Hypertension in the Berton, G., Cordiano, R., Mbaso, S., Atorvastatin in Patients With Hyperlipidemia?, 75A Elderly, 109A Javernaro, A., Guarnieri, G.L., Dal Black, H.: Impact of Newer Benetos, A., Safar, M., Guize, L.: Effects of Canton, A., De Toni, R., Mormino, Antihypertensive Agents on the Heart Rate on Cardiovascular and P., Winnicki, M., Palatini, P.: Management of Hypertension, 249A Noncardiovascular Mortality, 216A History of Hypertension Has a Benetos, A., see Pojoga, L., Topouchian, J. Black, H., Reed, J., Fitzsimmons, S., Shi, Y.: Great Predictive Value Toward Benishin, C.G., Pang, P.K.T., Lewanczuk, The Combination of Valsartan and One-Year Mortality After Acute Hydrochlorothiazide is Effective R.Z., Ren, J., Shan, J.: Effects of Myocardial Infarction, But only in Parathyroid Hypertensive Factor on and Well Tolerated in Essential Patients With Microalbuminuria, L-Type Calcium Channels and Hypertension, 70A 26A Voltage Gated Potassium Channels Black, H.R.: Management of Elderly in Vascular Smooth Muscle, 14A Berton, G., Palmieri, R., Cordiano, R., Patients With Systolic Blood Pianca, S., Mbaso, S., Dal Canton, Pressure 140-159 mm Hg, 253A Benishin, C.G., see Krylova, S.M., Lewanczuk, R.Z. A., De Toni, R., Mormino, P., Black, H.R.: Antihypertensive Therapy and Benovic, J., see Zhang, M. Cucchini, F., Palatini, P.: Prognostic Cardiovascular Disease: Impact of Benter, I.F., see Diz, D.I. Value of Hypertension For Early Effective Therapy on Disease Mortality After Myocardial Berardone, H., see Pineiro, D.J. Progression, 3S Berenson, G.S., see Urbina, E.M. Infarction, 229A Black, H.R.: Individualized Selection of Berensztein, C.S., see Vazquez Blanco, M. Berton, G., see Palatini, P., Vriz, O. Antihypertensive Drug Therapy for Berger, M., see Silverberg, D. Betsas, J.A., see Vyssoulis, G.P. Older Patients, 62S Berglund, G., see Fagerberg, B. Bettini, E., see Seccia, T.M. Black, H.R., Crocitto, M.T.: Number Berl, T., see Porush, J.G. Bettini, R., see Seccia, T.M. Needed to Treat: Solid Science or a Bernabei, R., see Zuccala, G. Bettoncelli, G., see Zaninelli, A. Path to Pernicious Rationing?, 128S